Methotrexate - Therakind

Drug Profile

Methotrexate - Therakind

Alternative Names: Jylamvo; Methotrexate oral solution - Therakind

Latest Information Update: 21 Feb 2017

Price : $50

At a glance

  • Originator Therakind
  • Class Abortifacients; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Glutamates; Pterins; Small molecules
  • Mechanism of Action Immunosuppressants; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Acute lymphoblastic leukaemia; Juvenile rheumatoid arthritis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 21 Feb 2017 Chemical structure information added
  • 01 Feb 2017 Preregistration for Psoriasis (Treatment-resistant) in European Union (PO)
  • 26 Jan 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of methotrexate oral solution for Rheumatoid arthritis, Psoriatic arthritis, Psoriasis (Treatment-resistant), Juvenile rheumatoid arthritis (In children, In adolescents) and Acute lymphoblastic leukaemia (In children, In adolescents, In adults, as a maintenance therapy) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top